Literature DB >> 22785134

Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques.

Yunosuke Matsuura1, Kinta Hatakeyama, Takuroh Imamura, Toshihiro Tsuruda, Yoshisato Shibata, Tatsuhiko Kodama, Kazuo Kitamura, Yujiro Asada.   

Abstract

AIM: To understand the differences between histopathological characteristics related to PTX3 (pentraxin 3) and CRP (C-reactive protein) in coronary atherosclerotic plaques. METHODS AND
RESULTS: To assess the localization of PTX3 and CRP in coronary plaque, immunohistochemistry was performed using 157 coronary artery specimens from 45 autopsied cases. Overall, immunoreactivity to CRP was more intense than that to PTX3 in lipid rich plaque; however, PTX3 was notably abundant in areas of intraplaque hemorrhage, in which CRP was quite sparse. On quantitative analysis, complicated plaques showed more immunopositive area of PTX3 than fibroatheroma, but with CRP, this trend disappeared. In addition, we examined the phenotype of macrophages in PTX3- and CRP-rich areas using CD163 staining (M2 macrophages). Consequently, these areas were differently characterized by the accumulation of macrophages with high and low magnitude of CD163 positivity, respectively. Next, we immunohistochemically investigated relationships among PTX3, CRP, histological components and clinical presentation in 73 coronary atherectomy specimens obtained from 35 and 38 patients with unstable (UAP) and stable angina pectoris (SAP), respectively. Both PTX3 and CRP were more intense in culprit plaques from patients with UAP than with SAP, and they significantly correlated with CD68 (pan macrophage)-positive areas; however, there was no correlation between PTX3 and CRP.
CONCLUSION: Although PTX3 and CRP were more enhanced in unstable than in stable coronary plaques, their distribution distinctly differed, suggesting that they play distinct biological roles in unstable plaques.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785134     DOI: 10.5551/jat.12526

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  10 in total

1.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

2.  Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors?

Authors:  Ayumi Nakamura; Shin-Ichiro Miura; Yuhei Shiga; Kenji Norimatsu; Yuiko Miyase; Yasunori Suematsu; Ryoko Mitsutake; Keijiro Saku
Journal:  Heart Vessels       Date:  2014-07-22       Impact factor: 2.037

3.  Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.

Authors:  N S Jenny; R S Blumenthal; R A Kronmal; J I Rotter; D S Siscovick; B M Psaty
Journal:  J Thromb Haemost       Date:  2014-06       Impact factor: 5.824

4.  Angiotensin II-accelerated vulnerability of carotid plaque in a cholesterol-fed rabbit model-assessed with magnetic resonance imaging comparing to histopathology.

Authors:  Beibei Sun; Huilin Zhao; Xiao Li; Hong Yao; Xiaosheng Liu; Qing Lu; Jieqing Wan; Jianrong Xu
Journal:  Saudi J Biol Sci       Date:  2017-01-27       Impact factor: 4.219

5.  Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome.

Authors:  Misa Tojo; Kaori Shintani-Ishida; Hajime Tsuboi; Mami Nakamura; Nozomi Idota; Hiroshi Ikegaya
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

6.  Monomeric C-reactive protein affects cell injury and apoptosis through activation of p38 mitogen-activated protein kinase in human coronary artery endothelial cells.

Authors:  Yong Zhang; Hongxia Cao
Journal:  Bosn J Basic Med Sci       Date:  2020-11-02       Impact factor: 3.363

7.  Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies.

Authors:  Kejun Ding; Zhewei Shi; Caizhen Qian; Xuan Yang
Journal:  Front Cardiovasc Med       Date:  2022-01-10

Review 8.  Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases.

Authors:  Fabrizia Bonacina; Andrea Baragetti; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Mediators Inflamm       Date:  2013-04-07       Impact factor: 4.711

9.  Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability.

Authors:  Akihiro Shindo; Hiroshi Tanemura; Kenichiro Yata; Kazuhide Hamada; Masunari Shibata; Yasuyuki Umeda; Fumio Asakura; Naoki Toma; Hiroshi Sakaida; Takao Fujisawa; Waro Taki; Hidekazu Tomimoto
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

10.  Age-Related Differences in the Association between Plasma High-Sensitivity C-Reactive Protein and Noncalcified or Mixed Coronary Atherosclerotic Plaques.

Authors:  Tiewei Li; Ning Chen; Zhengan Liu; Zhiming Shan; Geng Dong; Junmei Yang; Minglu Qi
Journal:  Mediators Inflamm       Date:  2020-04-28       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.